Table 1.
Measurements of PaCO2, PaO2 and mean arterial pressure (MAP) during baseline, hypoxic exposure and 60 minutes post-hypoxia.
| Treatment groups (+AIH) | PaCO2 (mmHg) | PaO2 (mmHg) | MAP (mmHg) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | hypoxia | 60min | baseline | hypoxia | 60min | baseline | hypoxia | 60min | |
| vehicle control
|
45.4±1.2 | 46.2±1.3 | 45.3±1.1 | 263±10 | 43±8† | 257±8 | 116±5 | 99±7† | 112±3 |
| 5-HT7 antagonist
|
45.6±0.6 | 46.8±0.9 | 46.1±0.6 | 288±9 | 33±5† | 273±11 | 112±3 | 87±8† | 103±5 |
| PKA inhibitor
|
46.2±1.1 | 45.8±0.7 | 46.9±1.0 | 252±12 | 37±2† | 244±8 | 112±5 | 91±6† | 111±4 |
| PKA activator | 46.7±0.6 | 47.0±1.1 | 46.8±0.6 | 276±4 | 39±2† | 255±6† | 109±4 | 86±6† | 100±4 |
|
| |||||||||
| (−AIH) groups | baseline | Equiv Time | 60min | baseline | Equiv Time | 60min | baseline | Equiv Time | 60min |
|
| |||||||||
| vehicle control
|
46.8±1.0 | 46.3±0.8 | 45.7±1.1 | 262±9 | 254±7 | 243±8 | 128±7 | 129±6 | 127±6 |
| 5-HT7 antagonist control
|
46.7±1.2 | 46.3±1.0 | 45.8±0.9 | 292±6 | 283±7 | 272±12 | 124±12 | 122±11 | 125±9 |
| PKA inhibitor control
|
46.8±0.7 | 47.1±0.8 | 47.5±0.8 | 280±5 | 273±7 | 269±6 | 120±5 | 122±5 | 122±4 |
| PKA activator control | 48.1±1.6 | 47.6±1.8 | 48.2±1.7 | 264±8 | 258±8 | 253±9 | 111±4 | 111±5 | 109±5 |
Values are means ± S.E.M.,
†
different than baseline, p<0.05.